Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 29.18M 25.59M 23.7M 21.81M 41.25M 2.79B 42.06M 283M 111M 1.37B 110M 107M 4.74B P/E 2026 *
-1.1x
P/E 2027 * -1.66x
Enterprise Value 29.18M 25.59M 23.7M 21.81M 41.25M 2.79B 42.06M 283M 111M 1.37B 110M 107M 4.74B EV / Sales 2026 *
-
EV / Sales 2027 * 2.26x
Free-Float
97.65%
Yield 2026 *
-
Yield 2027 * -
06-03 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
06-01 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
06-01 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
05-29 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
05-29 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
05-08 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
04-22 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
04-22 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
04-06 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
03-30 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-17 CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 CI
02-13 Actinium Pharmaceuticals, Inc. Announces Executive Changes, Effective as of February 27, 2026 CI
1 day-1.83%
1 week-5.31%
Current month-7.14%
1 month-9.00%
3 months-18.02%
6 months-32.59%
Current year-33.09%
1 week 0.9
Extreme 0.9001
1.05
1 month 0.9
Extreme 0.9001
1.11
Current year 0.9
Extreme 0.9001
1.53
1 year 0.9
Extreme 0.9001
1.89
3 years 0.9
Extreme 0.9001
10.24
5 years 0.9
Extreme 0.9001
15.12
10 years 0.9
Extreme 0.9001
64.5
Manager TitleAgeSince
Chief Executive Officer 62 08/06/2017
Chief Tech/Sci/R&D Officer - 31/05/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 31/12/2007
Chairman 62 30/09/2013
Director/Board Member 68 07/11/2013
Date Insider Type Main position Quantity % Market Cap.
17/08/25Tax

Chief Executive Officer

120,900 0.3876%
30/03/25Issuer sale

Chief Executive Officer

2,385,976 7.6484%
30/03/25Issuer sale

Director

184,984 0.5930%
Change 5-day change 1-year change 3-year change Capi.($)
-1.83%-5.31%-42.04%-87.27% 29.18M
-2.48%-3.13%+55.85%+89.65% 54.88B
-0.55%-6.57%+55.85%+128.31% 54.63B
-6.39%-2.78%+6.43%+417.12% 25.06B
-1.27%-3.51%-18.35%-17.24% 23.14B
-1.69%-0.64%+40.04%-0.48% 19.87B
+1.87%+4.16%+38.74%-26.42% 17.55B
-2.72%-0.60%+187.08%+351.91% 16.5B
-2.42%+1.00%+48.24%+635.77% 15.75B
-1.32%+0.54%+22.49%+188.53% 14.2B
Average -1.88%-1.26%+39.43%+167.99% 24.16B
Weighted average by Cap. -1.90%-1.56%+47.57%+165.58%

Financials

2026 *2027 *
Net sales - 12.93M 11.34M 10.5M 9.66M 18.28M 1.24B 18.63M 125M 49.09M 608M 48.54M 47.48M 2.1B
Net income -28.5M -25M -23.15M -21.3M -40.29M -2.73B -41.08M -276M -108M -1.34B -107M -105M -4.63B -23.27M -20.41M -18.9M -17.39M -32.9M -2.23B -33.54M -225M -88.36M -1.09B -87.37M -85.46M -3.78B
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
25
Date Price Change Volume
13/07/26 US$0.9050 -2.69% 69,937
10/07/26 US$0.9300 -4.12% 75,891
09/07/26 US$0.9700 0.00% 51,156
08/07/26 US$0.9700 -7.62% 72,605
07/07/26 US$1.050 +9.26% 228,039
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9300USD
Average target price
5.000USD
Spread / Average Target
+437.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock